NASDAQ : BVS
Bioventus Inc. — Key statistics
Healthcare · Medical Devices · United States
Last price 14.87 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.25B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.12B |
| Enterprise Value | 1.35B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 2, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 68.31M |
| Shares Outstanding | 84.09M |
| Shares Change (YoY) | +5.97% |
| Shares Change (QoQ) | +1.19% |
| Owned by Insiders (%) | 2.64% |
| Owned by Institutions (%) | 44.15% |
| Float | 34.30M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 17.04 |
| Forward PE | 16.71 |
| PS Ratio | 1.93 |
| Forward PS | 1.80 |
| PB Ratio | 3.98 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 11.88 |
| P/OCF Ratio | 11.57 |
| PEG Ratio | 1.52 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 24.86 |
| EV / Sales | 2.33 |
| EV / EBITDA | 16.89 |
| EV / EBIT | 22.34 |
| EV / FCF | 14.36 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.69 |
| Quick Ratio | 1.11 |
| Debt / Equity | 0.95 |
| Debt / EBITDA | 3.08 |
| Debt / FCF | 2.80 |
| Interest Coverage | 3.05 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 25.68% |
| Return on Assets (ROA) | 5.49% |
| Return on Invested Capital (ROIC) | 12.15% |
| Return on Capital Employed (ROCE) | 11.64% |
| Weighted Average Cost of Capital (WACC) | 7.44% |
| Revenue Per Employee | $612,472 |
| Profits Per Employee | $57,331 |
| Employee Count | 950 |
| Asset Turnover | 0.84 |
| Inventory Turnover | 2.07 |
Taxes
| Measure | Value |
|---|
| Income Tax | -22.84M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.64 |
| 52-Week Price Change | +96.82% |
| 50-Day Moving Average | 13.71 |
| 200-Day Moving Average | 10.90 |
| Relative Strength Index (RSI) | 43.98 |
| Average Volume (20 Days) | 409,320 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.18M |
| Short Previous Month | 3.16M |
| Short % of Shares Out | 3.78% |
| Short % of Float | 9.27% |
| Short Ratio (days to cover) | 7.53 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 581.85M |
| Gross Profit | 399.45M |
| Operating Income | 60.61M |
| Pretax Income | 38.64M |
| Net Income | 54.46M |
| EBITDA | 80.15M |
| EBIT | 60.61M |
| Earnings Per Share (EPS) | $0.78 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 30.39M |
| Total Debt | 263.75M |
| Net Cash | -233.36M |
| Net Cash Per Share | -$2.78 |
| Equity (Book Value) | 277.41M |
| Book Value Per Share | 3.35 |
| Working Capital | 105.08M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 96.87M |
| Capital Expenditures | -2.59M |
| Depreciation & Amortization | 19.54M |
| Net Borrowing | -27.90M |
| Free Cash Flow | 94.29M |
| FCF Per Share | $1.12 |
Margins
| Measure | Value |
|---|
| Gross Margin | 68.65% |
| Operating Margin | 10.42% |
| Pretax Margin | 6.64% |
| Profit Margin | 9.36% |
| EBITDA Margin | 13.77% |
| EBIT Margin | 10.42% |
| FCF Margin | 16.20% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -5.97% |
| Shareholder Yield | -5.97% |
| Earnings Yield | 5.87% |
| FCF Yield | 8.41% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $17.60 |
| Price Target Difference | 32.08% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 6.56% |
| EPS Growth Forecast (3Y) | 15.95% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 1.54 |
| Piotroski F-Score | 8 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |